Dylan Morris has worked in a variety of roles since 2018. In 2021, they became a Managing Director at Insight Partners, a Board Director at ArrePath, and a Board Observer at NanoMosaic Inc. In 2022, they will become a Board Director at DEM Biopharma, Inc., Unlearn.AI, and Gameto. Prior to that, they were a Board Director at Dyno Therapeutics from 2018, a Board Director at Switch Therapeutics from 2020, a Board Director at Deciduous Therapeutics from 2019, and a Board Observer at Exo Therapeutics from 2019.
Dylan Morris is currently pursuing a Graduate Research degree in Biochemistry and Molecular Biophysics at Caltech. Dylan previously obtained an AB in Computer Science from Harvard University.
View in org chart
View in org chart
January, 2021 - present